VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02RESULTS OF OPERATION AND FINANCIAL CONDITION
ITEM 7.01REGULATION FD DISCLOSURE
On March 21, 2019, Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, issued a press release announcing its 1st quarter ended January 31st 2019 financial results of operations. The Company recorded 1st quarter revenues of $192,895 vs $87,185 an increase of 121% over the same comparative quarter last year. In addition, Stem Cell treatments accounted for 71% of the revenues up from 62% of the revenues in the prior comparative quarter last year. Current quarter stem cell revenues were $137,123 for the 1st quarter ended January 31, 2019 vs $54,152 for the first quarter ended January 31, 2018. A copy of the Press Release is filed herewith as Exhibit 99.1.
The information in this Current Report on Form 8-K furnished to Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, and they shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. By filing this Current Report on Form 8-K and furnishing this information to Item 7.01, The Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including Exhibit 99.1, that is required to be disclosed solely by Regulation FD.
VITRO DIAGNOSTICS INC Exhibit
EX-99.1 2 vitro_99ez1.htm PRESS RELEASE Vitro Biopharma 1st Quarter ended January 31st 2019 Financial Results of Operations Golden,…
To view the full exhibit click
About VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG)
Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company’s clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.